Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features

Arthritis Research and Therapy

Volumn 14, Issue 2, 2012, Pages

  Celis, Raquel ^a   Planell, Núria ^b   Fernández Sueiro, José L ^c   Sanmartí, Raimon ^a   Ramírez, Julio ^a   González Álvaro, Isidoro ^d   Pablos, José L ^e   Cañete, Juan D ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Rheumatology Division   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD20 ANTIGEN; CD3 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 23P19; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MECA 79 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; CYTOKINE;

ADULT; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; LYMPHOID CELL; MALE; PSORIATIC ARTHRITIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SYNOVIAL FLUID; SYNOVIUM; TH1 CELL; TH17 CELL; TH2 CELL; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; LYMPH; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ADULT; ARTHRITIS, PSORIATIC; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH; MALE; MIDDLE AGED; SYNOVIAL FLUID;

EID: 84860222506     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3817     Document Type: Article

References (40)

1. Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009, 11:214. 10.1186/ar2580, 2688229, 19232079.
2. Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, Cañete JD, Boots AM, Veys EM, De Keyser F. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005, 7:R569-R580. 10.1186/ar1698, 1174942, 15899044.
3. Cañete JD, Santiago B, Cantaert T, Sanmartí R, Palacin A, Celis R, Graell E, Gil-Torregrosa B, Baeten D, Pablos JL. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007, 66:720-726. 10.1136/ard.2006.062042, 1954653, 17223654.
4. Cañete JD, Celis R, Moll C, Izquierdo E, Marsal S, Sanmartí R, Palacín A, Lora D, de la Cruz J, Pablos JL. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009, 68:751-756. 10.1136/ard.2008.089284, 18495732.
5. Cantaert T, Kolln J, Timmer T, van der Pouw Kraan TC, Vandooren B, Thurlings RM, Cañete JD, Catrina AI, Out T, Verweij CL, Zhang Y, Tak PP, Baeten D. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol 2008, 181:785-794.
6. Weyand CM, Kurtin PJ, Goronzy JJ. Ectopic lymphoid organogenesis: a fast track for autoimmunity. Am J Pathol 2001, 159:787-793. 10.1016/S0002-9440(10)61751-8, 1850453, 11549568.
7. Vander Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L, Mielants H, Veys EM, Baeten D, De Keyser F. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005, 64:1145-1149. 10.1136/ard.2004.032177, 1755603, 15695535.
8. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001, 167:4710-4718.
9. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, . The CASPAR Study Group Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673. 10.1002/art.21972, 16871531, The CASPAR Study Group.
10. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012, 66:369-375. 10.1016/j.jaad.2011.01.022, 22041254.
11. Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, Yanni G, Fitzgerald O, Bresnihan B, Caporali R, Montecucco C, Uguccioni M, Pitzalis C. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 2005, 35:1347-1359. 10.1002/eji.200425830, 15832291.
12. RayBiotech. , http://www.raybiotech.com
13. Ortiz AM, Laffon A, Gonzalez-Alvaro I. CD69 expression on lymphocytes and interleukin-15 levels in synovial fluids from different inflammatory arthropathies. Rheumatol Int 2002, 21:182-188. 10.1007/s00296-001-0161-z, 11958434.
14. R Development Core Team R: A Language and Environment For Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2010, ISBN 3-900051-07-0, R Development Core Team., http://www.R-project.org
15. Timmer TC, Baltus B, Vondenhoff M, Huizinga TW, Tak PP, Verweij CL, Mebius RE, van der Pouw Kraan TC. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum 2007, 56:2492-2502. 10.1002/art.22748, 17665400.
16. Weyand CM, Kang YM, Kurtin PJ, Goronzy JJ. The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis. Curr Opin Rheumatol 2003, 15:259-266. 10.1097/00002281-200305000-00013, 12707579.
17. Thurlings RM, Wijbrandts CA, Mebius RE, Cantaert T, Dinant HJ, van der Pouw-Kraan TC, Verweij CL, Baeten D, Tak PP. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum 2008, 58:1582-1589. 10.1002/art.23505, 18512774.
18. Bugatti S, Manzo A, Vitolo B, Fusetti C, Caporali R, Pitzalis C, Montecucco C. Clinical, radiographic and biomolecular features of B cell synovitis in rheumatoid arthritis [Abstract]. Arthritis Rheum 2011, 62:S110.
19. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, Goronzy JJ, Weyand CM. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001, 167:1072-1080.
20. Braun A, Takemura S, Vallejo AN, Goronzy JJ, Weyand CM. Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum 2004, 50:2140-2150. 10.1002/art.20356, 15248211.
21. Wengner AM, Höpken UE, Petrow PK, Hartmann S, Schurigt U, Bräuer R, Lipp M. CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum 2007, 56:3271-3283. 10.1002/art.22939, 17907173.
22. Bugatti S, Manzo A, Bombardieri M, Vitolo B, Humby F, Kelly S, Montecucco C, Pitzalis C. Synovial tissue heterogeneity and peripheral blood biomarkers. Curr Rheumatol Rep 2011, 13:440-448. 10.1007/s11926-011-0201-y, 21847543.
23. Tang C, Chen S, Qian H, Huang W. Interleukin-23 as a target drug for autoimmune inflammatory diseases. Immunology 2011, 135:112-124.
24. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748. 10.1038/nature01355, 12610626.
25. Melis L, Vandooren B, Kruithof E, Jacques P, De Vos M, Mielants H, Verbruggen G, De Keyser F, Elewaut D. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010, 69:618-623. 10.1136/ard.2009.107649, 19196728.
26. Rasmussen TK, Andersen T, Hvid M, Hetland ML, Hørslev-Petersen K, Stengaard-Pedersen K, Holm CK, Deleuran B. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol 2010, 37:2014-2020. 10.3899/jrheum.100259, 20682664.
27. Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J, Bruce IN, Barton A. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008, 58:3705-3709. 10.1002/art.24128, 3001112, 19035472.
28. Bowes J, Orozco G, Flynn E, Ho P, Brier R, Marzo-Ortega H, Coates L, McManus R, Ryan AW, Kane D, Korendowych E, McHugh N, FitzGerald O, Packham J, Morgan AW, Bruce IN, Barton A. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 2011, 70:1641-1644. 10.1136/ard.2011.150102, 3147229, 21623003.
29. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009, 373:633-640. 10.1016/S0140-6736(09)60140-9, 19217154.
30. Gaston JS, Goodall JC, Baeten D. Interleukin-23: a central cytokine in the pathogenesis of spondyloarthritis. Arthritis Rheum 2011, 63:3668-3671. 10.1002/art.30600, 22127689.
31. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000, 43:1244-1256. 10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2, 10857783.
32. Kane D, Gogarty M, O'Leary J, Silva I, Bermingham N, Bresnihan B, Fitzgerald O. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004, 50:3286-3295. 10.1002/art.20518, 15476228.
33. McInnes IB, Liew FY. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 1998, 19:75-79. 10.1016/S0167-5699(97)01205-X, 9509762.
34. Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Cañete JD, Baeten D. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012, 64:99-109. 10.1002/art.33396, 21968742.
35. González-Álvaro I, Ortiz AM, Alvaro-Gracia JM, Castañeda S, Díaz-Sánchez B, Carvajal I, García-Vadillo JA, Humbría A, López-Bote JP, Patiño E, Tomero EG, Vicente EF, Sabando P, García-Vicuña R. Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS One 2011, 6:e29492. 10.1371/journal.pone.0029492, 3248461, 22242124.
36. Yeremenko N, Baeten D. IL-17 in spondyloarthritis: is the T-party over?. Arthritis Res Ther 2011, 13:115. 10.1186/ar3351, 3218894, 21722352.
37. Nozato K, Fujita J, Kawaguchi M, Ohara G, Morishima Y, Ishii Y, Huang SK, Kokubu F, Satoh H, Hizawa N. IL-17F induces CCL20 in bronchial epithelial cells. J Allergy (Cairo) 2011, 2011:587204.
38. Alenius GM, Eriksson C, Rantapää Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?. Clin Exp Rheumatol 2009, 27:120-123.
39. Wahl SM, Orenstein JM, Chen W. TGF-beta influences the life and death decisions of T lymphocytes. Cytokine Growth Factor Rev 2000, 11:71-79. 10.1016/S1359-6101(99)00030-1, 10708954.
40. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, Tak PP. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: implication for pathogenesis and evaluation of treatment. Arthritis Rheum 2002, 46:2034-2038. 10.1002/art.10556, 12209505.